Merck & Co., Inc. Q2 Earnings Call Highlights

3 weeks ago 29

MarketBeat

Wed, August 5, 2026 astatine 5:04 AM CDT 7 min read

Key Points

Interested successful Merck & Co., Inc.? Here are 5 stocks we similar better.
Q2 gross roseate 5% to $16.6 billion, driven by oncology, carnal wellness and newer launches. Merck reported a $0.13 per-share nonaccomplishment owed mostly to a $5.7 cardinal complaint for the Terns Pharmaceuticals acquisition and raised its 2026 gross outlook to $66.3 billion–$67.3 billion.
Oncology remained the superior maturation engine: KEYTRUDA-family income accrued 4% to $8.4 billion, portion WELIREG income climbed 67%. Merck besides reported affirmative Phase III results for its sac-TMT crab campaigner successful endometrial cancer.
Merck expanded its maturation pipeline and merchandise portfolio with the FDA support of LIPFENDRA, an oral PCSK9 inhibitor, and continued momentum from WINREVAIR, OHTUVAYRE and CAPVAXIVE. Management besides expressed assurance that caller products volition assistance offset the eventual interaction of KEYTRUDA's nonaccomplishment of exclusivity.

Amylyx Stock: Why the Full Pipeline Story Matters

Merck & Co., Inc. (NYSE:MRK) reported second-quarter gross of $16.6 billion, up 5% from a twelvemonth earlier, driven by oncology, carnal wellness and contributions from newer merchandise launches. Revenue accrued 4% excluding overseas exchange, according to Chief Financial Officer Caroline Litchfield.

The institution reported a nonaccomplishment of $0.13 per stock for the quarter, reflecting a $2.31-per-share one-time complaint tied to its acquisition of Terns Pharmaceuticals. Merck completed the Terns acquisition during the quarter, adding MK-4208, a late-stage campaigner for definite patients with chronic myeloid leukemia. The acquisition generated a $5.7 cardinal complaint successful the quarter.

→ SpaceX's First Earnings Report Could Decide Whether Shorts oregon Bulls Have Control

Merck Just Made a Big Bet connected a New Cancer Growth Engine

Merck raised and narrowed its 2026 gross outlook to a scope of $66.3 cardinal to $67.3 billion, representing maturation of 2% to 4%, including an astir one-percentage-point payment from overseas speech astatine mid-July speech rates. The institution projected full-year adjusted net per stock of $2.66 to $2.76, including the Terns-related upfront complaint and ongoing costs associated with advancing MK-4208 and financing the transaction.

Oncology Remains the Largest Growth Driver

Sales from the KEYTRUDA family, including KEYTRUDA and KEYTRUDA QLEX, roseate 4% to $8.4 billion. Litchfield said maturation was driven by uptake successful earlier-stage cancers, continued request successful metastatic indications, usage successful bosom and cervical cancers, and accrued utilization of KEYTRUDA with PADCEV successful locally precocious oregon metastatic urothelial cancer.

Read Entire Article